ocular diseases

Pharma

Roivant eyes Humira's throne in NIU after Lisraya ph. 3 win

With the ink barely dry on Lisraya’s first approval, Roivant is wasting little time making the case for a larger immune-mediated kingdom for the drug.

Fraiser Kansteiner Oct 22, 2026 8:04am

Cloudbreak surveys trial volunteers on pterygium struggles

Apr 8, 2024 7:15am

Sandoz launches rival to AbbVie's popular eye med

Apr 14, 2022 11:31am